Syndax Pharmaceuticals Stock Analysis
SNDX Stock | USD 13.08 0.08 0.62% |
Syndax Pharmaceuticals is undervalued with Real Value of 18.4 and Target Price of 36.46. The main objective of Syndax Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Syndax Pharmaceuticals is worth, separate from its market price. There are two main types of Syndax Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Syndax Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Syndax Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Syndax Stock trading window is adjusted to America/New York timezone.
Syndax |
Syndax Stock Analysis Notes
About 99.0% of the company shares are owned by institutional investors. The book value of Syndax Pharmaceuticals was at this time reported as 4.28. The company has Price/Earnings (P/E) ratio of 126.11. Syndax Pharmaceuticals recorded a loss per share of 3.66. The entity had not issued any dividends in recent years. Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts. Syndax Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people. To find out more about Syndax Pharmaceuticals contact Michael MBA at 781 419 1400 or learn more at https://www.syndax.com.Syndax Pharmaceuticals Investment Alerts
Syndax Pharmaceuticals generated a negative expected return over the last 90 days | |
Syndax Pharmaceuticals has high historical volatility and very poor performance | |
Net Loss for the year was (209.36 M) with loss before overhead, payroll, taxes, and interest of (48.19 M). | |
Syndax Pharmaceuticals currently holds about 350.71 M in cash with (160.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.82. | |
Syndax Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Over 99.0% of the company shares are owned by institutional investors | |
Latest headline from investors.com: Heres How Donald Trump Could Shake Up Health Care And Biotech Stocks |
Syndax Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Syndax Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
27th of February 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Syndax Largest EPS Surprises
Earnings surprises can significantly impact Syndax Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2021-03-08 | 2020-12-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2019-11-07 | 2019-09-30 | -0.47 | -0.41 | 0.06 | 12 | ||
2016-08-09 | 2016-06-30 | -0.53 | -0.47 | 0.06 | 11 |
Syndax Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Syndax Pharmaceuticals' ESG score is a quantitative measure that evaluates Syndax Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Syndax Pharmaceuticals' operations that may have significant financial implications and affect Syndax Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Syndax Stock Institutional Investors
Shares | Woodline Partners Lp | 2024-09-30 | 1.9 M | Franklin Resources Inc | 2024-09-30 | 1.8 M | Stempoint Capital Lp | 2024-09-30 | 1.7 M | Goldman Sachs Group Inc | 2024-09-30 | 1.6 M | First Turn Management Llc | 2024-09-30 | 1.2 M | Millennium Management Llc | 2024-09-30 | 1.1 M | Soleus Capital Management, L.p. | 2024-09-30 | 1.1 M | Sphera Funds Management Ltd. | 2024-09-30 | 1 M | Aisling Capital Management Lp | 2024-09-30 | 1 M | Blackrock Inc | 2024-09-30 | 8.2 M | Kynam Capital Management, Lp | 2024-09-30 | 5.8 M |
Syndax Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.12 B.Syndax Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.31) | (0.32) | |
Return On Capital Employed | (0.37) | (0.39) | |
Return On Assets | (0.31) | (0.32) | |
Return On Equity | (0.43) | (0.41) |
Management Efficiency
Syndax Pharmaceuticals has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8188) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2025. Return On Capital Employed is likely to drop to -0.39 in 2025. At this time, Syndax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 38.6 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 742.9 K in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 7.10 | 7.45 | |
Tangible Book Value Per Share | 7.10 | 7.45 | |
Enterprise Value Over EBITDA | (4.79) | (5.03) | |
Price Book Value Ratio | 2.47 | 2.59 | |
Enterprise Value Multiple | (4.79) | (5.03) | |
Price Fair Value | 2.47 | 2.59 | |
Enterprise Value | 1.1 B | 1.2 B |
Management at Syndax Pharmaceuticals focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Technical Drivers
As of the 18th of January 2025, Syndax Pharmaceuticals has the Variance of 18.03, coefficient of variation of (802.74), and Risk Adjusted Performance of (0.1). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Syndax Pharmaceuticals, as well as the relationship between them.Syndax Pharmaceuticals Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Syndax Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Syndax Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Syndax Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syndax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syndax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syndax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gallagher Neil over three months ago Acquisition by Gallagher Neil of 69375 shares of Syndax Pharmaceuticals at 22.28 subject to Rule 16b-3 | ||
Jarrett Jennifer over six months ago Acquisition by Jarrett Jennifer of 17000 shares of Syndax Pharmaceuticals subject to Rule 16b-3 | ||
Peter Ordentlich over six months ago Acquisition by Peter Ordentlich of 90000 shares of Syndax Pharmaceuticals at 28.55 subject to Rule 16b-3 | ||
Briggs Morrison over six months ago Acquisition by Briggs Morrison of 52855 shares of Syndax Pharmaceuticals at 8.77 subject to Rule 16b-3 | ||
Dennis Podlesak over six months ago Acquisition by Dennis Podlesak of 34000 shares of Syndax Pharmaceuticals subject to Rule 16b-3 | ||
Peter Ordentlich over a year ago Exercise or conversion by Peter Ordentlich of 7572 shares of Syndax Pharmaceuticals subject to Rule 16b-3 |
Syndax Pharmaceuticals Outstanding Bonds
Syndax Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Syndax Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Syndax bonds can be classified according to their maturity, which is the date when Syndax Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
SNV 5625 15 FEB 28 Corp BondUS87164DVJ61 | View | |
SYNCHRONY FINL 45 Corp BondUS87165BAG86 | View | |
SYNCHRONY FINL 395 Corp BondUS87165BAM54 | View | |
SYNCHRONY FINL 37 Corp BondUS87165BAL71 | View | |
SYF 4875 13 JUN 25 Corp BondUS87165BAS25 | View | |
SYF 2875 28 OCT 31 Corp BondUS87165BAR42 | View | |
SYF 725 02 FEB 33 Corp BondUS87165BAU70 | View | |
SNX 265 09 AUG 31 Corp BondUS87162WAK62 | View |
Syndax Pharmaceuticals Predictive Daily Indicators
Syndax Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Syndax Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Syndax Pharmaceuticals Corporate Filings
8K | 20th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 6th of December 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 21st of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Syndax Pharmaceuticals Forecast Models
Syndax Pharmaceuticals' time-series forecasting models are one of many Syndax Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Syndax Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Syndax Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Syndax Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Syndax shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Syndax Pharmaceuticals. By using and applying Syndax Stock analysis, traders can create a robust methodology for identifying Syndax entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.16 | 0.17 | |
Operating Profit Margin | 0.17 | 0.18 | |
Net Profit Margin | 0.16 | 0.17 | |
Gross Profit Margin | 0.90 | 0.80 |
Current Syndax Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Syndax analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Syndax analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
36.46 | Strong Buy | 15 | Odds |
Most Syndax analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Syndax stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Syndax Pharmaceuticals, talking to its executives and customers, or listening to Syndax conference calls.
Syndax Stock Analysis Indicators
Syndax Pharmaceuticals stock analysis indicators help investors evaluate how Syndax Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Syndax Pharmaceuticals shares will generate the highest return on investment. By understating and applying Syndax Pharmaceuticals stock analysis, traders can identify Syndax Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 74.5 M | |
Common Stock Shares Outstanding | 70.4 M | |
Total Stockholder Equity | 554.2 M | |
Property Plant And Equipment Net | 1.5 M | |
Cash And Short Term Investments | 577.6 M | |
Cash | 295.4 M | |
Accounts Payable | 10 M | |
Net Debt | -293.8 M | |
50 Day M A | 15.4235 | |
Total Current Liabilities | 58.1 M | |
Other Operating Expenses | 230 M | |
Non Current Assets Total | 32 M | |
Non Currrent Assets Other | 680 K | |
Stock Based Compensation | 31 M |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.